Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. - sprookjes - yvandenbroek - TriplyDB

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.

http://www.wikidata.org/entity/Q39474140

about

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs The Concept of Hormesis in Cancer Therapy - Is Less More?Immune regulation of bone metastasis Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Delicate balance among three types of T cells in concurrent regulation of tumor immunity.Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.Adoptive immunotherapy of metastatic breast cancer: present and future.What is the role of chemotherapy in the treatment of melanoma?Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?Emerging roles of regulatory T cells in tumour progression and metastasis.Brain Tumor Immunotherapy: What have We Learned so Far?Clinical overview of metronomic chemotherapy in breast cancer.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Targeting regulatory T cells in tumors.Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.

P2860

Q26742012-56A87C38-578C-4932-B070-C553A0F69408 Q26745444-E76AEFBE-6435-47F9-AC52-4DB0F3E97A68 Q26745462-DC505B2E-B5D6-4A12-B0B0-7A39B2FCE2CA Q26751245-0B655B92-13A0-4DBF-8751-BACF54D155ED Q26781522-D1CDF05C-971A-46EB-AED1-14FA239B10EC Q26800519-A20B59FA-9F0E-4EE7-9EE1-CBD9C23BAA67 Q27005871-558DA79E-D91D-4855-A152-EE00069EA83B Q28066486-C5EEE11B-4B3C-47D7-8D4A-FA993933697D Q33607086-CA18F69C-31B1-4AB4-9DD0-302094A36820 Q33738937-29E5D857-E492-4098-AAA7-1853609F663C Q34173001-E8901C2E-1CA6-4566-98A7-55317011288A Q35078064-CA7A06B4-D9A5-4DF6-AF37-0E77DC24D8EB Q35798947-7A070E8C-60A9-49A4-9376-B6B84941B755 Q36212905-A1238B25-98D9-44F7-AA02-2DE36A0E0EAD Q36282739-824FF29F-BBB8-4FA8-B9A2-380A115F81A3 Q36388495-C39A461A-882F-403F-8E66-ADAD550A138C Q36562375-0398D729-02B3-4A86-BCB5-1F90EBE9F194 Q36600960-01510E7D-702F-49B2-9B95-B205E14EF231 Q36710972-7FF853BF-6082-4F8C-B01A-8D893ACB70A2 Q36755513-639AF23D-2D05-4CBB-9483-9C8995EE01E3 Q36791766-9F930668-FB8E-453B-A1C4-14BF66995115 Q37214382-31547E0D-17BF-4DEA-8F03-BE1E963A4E2B Q37459043-B1ABA806-DBA2-4BD0-9EA0-6B5A87CA9482 Q37531844-DF0B460C-0437-41E7-9D95-D0A927C6F48B Q38023842-BBE7A95C-A1FD-48C2-9F1B-8B130BBC4CCA Q38087885-154EF199-50CF-417C-90BD-D5C0405CEF7B Q38110540-98D285E0-2D94-4410-93DD-A194DADAEB9C Q38115968-A648BF21-2A06-40A5-A8C1-6D474777E1D2 Q38167887-67F9E72D-13F6-40C2-99ED-883923B77D3F Q38168953-84EEBB15-DFBE-4A73-8B2A-29E8A8290FB3 Q38171325-5969C2EF-0C23-46BB-93B0-FC7569993C7F Q38193716-A38254A1-2FB2-4B37-B218-8ABDF64254AC Q38239661-BBFC782A-074D-4172-BEA7-A989F98D9DDF Q38264092-EC63AF8F-3F05-4264-BD43-5B6C0909A64B Q38542113-4F462AA3-F9E4-42F9-90E7-C88C5F515322 Q38560651-75024252-D85A-44F4-AEE5-2D1D73E7C0AF Q38636430-3F019211-D856-49E8-BAF4-9B7071C4539C Q38638654-CA5232CC-931B-4102-A128-52639931296F Q38703565-BC7BA513-2A8D-4027-8693-67E4D306E1C5 Q38741186-09C12B73-A4C4-44B6-BCAD-8CA89199E92D

P2860

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.

http://www.wikidata.org/entity/Q39474140

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@en

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@nl

type

label

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@en

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@nl

prefLabel

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@en

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@nl

P1433

Q39474140-9DAC9E97-A5DA-4215-A50E-A49D05CA8A45

P1476

Q39474140-B9E05057-5722-4030-B3B8-2FF8FD475314

P2093

Q39474140-00D09662-56A6-491B-9B2D-BD5D6E24B535

Q39474140-2EDC5184-D687-4B36-A3CC-7D36F6867E5B

Q39474140-6A3E4A7E-9875-483C-A40E-102514C49BD1

Q39474140-7254F2A2-C0AD-4278-B00E-359A5F19E06E

Q39474140-78005159-43B8-426F-9775-B80752EB0F3A

Q39474140-85FCD3C5-5252-4C8E-9C5C-4C9FBBAF08BF

Q39474140-89EE712A-723D-4266-8B97-A88C78D35D43

Q39474140-DE99C70F-1EB2-4310-826D-0FB7A859CABA

Q39474140-E543A335-49F6-403A-AE9B-115E10554415

Q39474140-EB4FE5AB-5D33-4A26-8AE8-0532D21E37DD

P2860

Q39474140-0621C3F4-2672-48A3-9B49-56810248E5A7

Q39474140-1CB13059-8E2F-4A79-8FF9-58B257AF4C22

Q39474140-355C2D9A-B2AF-431C-9883-A35274317E3E

Q39474140-38480F61-14B6-46A0-9A8B-81BE9B3CEACD

Q39474140-43825FDA-FE72-4B2A-87BC-B9B703F22B2C

Q39474140-62421F8E-7C1D-4C14-97F8-8AB3BDB92258

Q39474140-7670E188-5A2A-469C-9D17-0BE02E2A260F

Q39474140-86354C05-E262-4F00-BC6A-B37429117BD6

Q39474140-88DE72BD-BABD-401D-B6B7-031718F09AE4

Q39474140-905CF0F4-B2BA-4C01-A5F3-ED821C4A8260

P2888

Q39474140-754C2E94-1591-4536-A753-298CB027AC50

P304

Q39474140-2CAD9369-8D7E-421D-90A1-35D4EC8D589A

P31

Q39474140-C009ABA6-2902-4CF9-B1F9-195A74A6FED6

P356

Q39474140-54E2EEF9-018D-44E1-A3AF-21BDC81D9AE2

P433

Q39474140-C96D2CBF-5771-4C50-BB75-13793229D61C

P478

Q39474140-EE7C449E-86BF-4B3D-9C89-3532274149C4

P50

Q39474140-B6F0AD37-013E-4164-9131-126558D64D7F

P577

Q39474140-0D2B5A5C-431E-4A1B-8DB0-E0EC71C0DDC8

P698

Q39474140-8C847349-BC05-48CD-9109-7051B8F4FBA5

P921

Q39474140-8B2E8BAC-B5C1-46DD-9844-0F928101F6EF

P356

S00262-011-1106-3

P1433

Cancer Immunology, Immunotherapy

P1476

Metronomic cyclophosphamide tr ...... effects and clinical outcome.

@en

P2093

Christof Sohn

http://www.w3.org/2001/XMLSchema#string

Christoph Domschke

http://www.w3.org/2001/XMLSchema#string

Florian Schuetz

http://www.w3.org/2001/XMLSchema#string

Janina Thum

http://www.w3.org/2001/XMLSchema#string

Joachim Rom

http://www.w3.org/2001/XMLSchema#string

Joerg Heil

http://www.w3.org/2001/XMLSchema#string

Maria Blumenstein

http://www.w3.org/2001/XMLSchema#string

Natalija Stoiber

http://www.w3.org/2001/XMLSchema#string

Philipp Beckhove

http://www.w3.org/2001/XMLSchema#string

Sarah Schott

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

How regulatory T cells work

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Regulatory T cells: key controllers of immunologic self-tolerance.

A human cell line from a pleural effusion derived from a breast carcinoma.

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Interleukin 2 signaling is required for CD4(+) regulatory T cell function.

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

P2888

s00262-011-1106-3

P304

353-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1106-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Schneeweiss

P577

2011-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21915801

http://www.w3.org/2001/XMLSchema#string

P921